Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia.
It has been demonstrated that hairy cell leukemia (HCL) can be efficiently treated by various preparations of alpha interferons (IFN). Nevertheless, there are several open questions, such as the route, mode and dosage of IFN application. These variables of IFN treatment may be critical since a myelosuppressive effect of IFN, which is commonly seen in the initial phase of treatment, can result in further deterioration of the already impaired platelet production in advanced HCL. The present study shows that serious side effects can be avoided and the flu-like syndromes described by others almost completely reduced by s.c. application of IFN via a portable pump during a daily 8 h period. IFN is initially given five times a week and the daily dose is adjusted according to the actual platelet count. The efficiency controls show that the increase of platelets in the peripheral blood, which is most critical in advanced HCL, may be seen earlier by this than by other protocols, which usually recommend higher daily doses of IFN and only three instead of five weekly applications.
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000276:immunology; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D007958:Leukocyte Count; D008297:Male; D010976:Platelet Count
D007370:Interferon Type I